ResMed (NYS: RMD) is expected to report Q4 earnings on Aug. 2. Here's what Wall Street wants to see.
The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict ResMed's revenues will expand 8.6% and EPS will improve 25.6%.
The average estimate for revenue is $371.3 million. On the bottom line, the average EPS estimate is $0.49.
Last quarter, ResMed booked revenue of $349.1 million. GAAP reported sales were 11% higher than the prior-year quarter's $313.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.46. GAAP EPS of $0.44 for Q3 were 29% higher than the prior-year quarter's $0.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.3%, 200 basis points better than the prior-year quarter. Operating margin was 22.2%, 180 basis points better than the prior-year quarter. Net margin was 18.5%, 150 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.36 billion. The average EPS estimate is $1.72.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 171 members out of 185 rating the stock outperform, and 14 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give ResMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $30.87.
The healthcare investing landscape is littered with also-rans and a few major winners. Is ResMed the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add ResMed to My Watchlist.
The article Can ResMed Meet These Numbers? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.